Evidence map›Paper›PMID 24453969›Full record

Trial reportPLoS pathogens2014

HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets.

Rujun Song, Irene Lisovsky, Bertrand Lebouché, Jean-Pierre Routy, Julie Bruneau, Nicole F Bernard

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 63 citations in OpenAlex.

  1. NK Cell Activity and CD57Frontiers in immunology · 2020
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Innate Immune Response Against HIV-1.Advances in experimental medicine and biology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rujun SongResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada ; Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Irene LisovskyResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada ; Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Bertrand LebouchéChronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada ; Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
Jean-Pierre RoutyDivision of Experimental Medicine, McGill University, Montreal, Quebec, Canada ; Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada ; Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Julie BruneauCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada ; Department of Family Medicine, Université de Montréal, Montreal, Quebec, Canada.
Nicole F BernardResearch Institute of the McGill University Health Centre, Montreal, Quebec, Canada ; Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada ; Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada ; Division of Clinical Immunology, McGill University Health Centre, Montreal, Quebec, Canada.
McGill University Health Centre · CAMcGill University · CAUniversité de Montréal · CA

Funding

Canadian Institutes of Health Research HOP-123800Canadian Institutes of Health Research HVI-79515
6 · The paper itself

Abstract

Carriage of the genetic combination encoding a high expression inhibitory Killer Immunoglobulin-like Receptor (KIR)3DL1 with its ligand, HLA-B*57 (*h/*y+B*57) is associated with slower time to AIDS and better HIV viral load control than being a Bw6 homozygote (Bw6hmz). Natural Killer (NK) cells from *h/*y+B*57 carriers receive potent educational signals through HLA-B*57 KIR3DL1 ligation leading to high functional potential. NK cells from Bw6hmz are not educated through KIR3DL1 because Bw6 antigens do not interact with this inhibitory receptor. To better understand the impact of KIR/HLA combinations on NK cell mediated anti-viral activity we measured NK cell mediated inhibition of HIV replication in autologous infected CD4 (iCD4) cells by assessing the frequency of p24 positive CD4 targets and supernatant levels of HIV p24 longitudinally in the presence versus absence of NK cells. Forty-seven HIV uninfected subjects were studied, including carriers of *h/*y+B*57, a low expression KIR3DL1 genotype with HLA-B*57 termed *l/*x+B*57, a genotype designated 3DS1+*80I and Bw6hmz. NK cells from *h/*y+B*57 carriers, like those from 3DS1+*80I subjects, inhibited HIV replication in autologous iCD4 cells better than those from Bw6hmz and *l/*x+B*57 carriers. Cell contact between NK and iCD4 cells activated NK cells to inhibit viral replication in a non-contact dependent fashion through secretion of CC-chemokines. iCD4 stimulated NK cells from *h/*y+B*57 and 3DS1+*80I carriers produced higher levels of CC-chemokines than those from Bw6hmz or *l/*x+B*57 carriers. Higher levels of CC-chemokines were produced by KIR3DL1(+) than KIR3DL1(-) NK cells. We conclude that NK-mediated inhibition of viral replication in autologous iCD4 cells is partially due to a block at the level of HIV entry into new targets by secreted CC-chemokines.

Indexed as

GenotypeImmunity, CellularAdultAgedCD4-Positive T-LymphocytesFemaleHIV-1HIV InfectionsHLA-B AntigensHumansKiller Cells, NaturalMaleMiddle AgedReceptors, KIR3DL1Virus ReplicationHLA-B57 antigenHLA-B AntigensKIR3DL1 protein, humanReceptors, KIR3DL1

Identifiers

PMID24453969
PMCPMC3894215
OpenAlexW2070712449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.